Sign Out
Patients with known hypersensitivity to domperidone, rabeprazole or substituted benzimidazoles, or to any of the ingredients of Rablet-D.
Patients with prolactin-releasing pituitary tumour (prolactinoma).
Rablet-D should not be used in patients with severe hepatic impairment.
Domperidone should not be used when stimulation of gastric motility could be harmful, eg, gastrointestinal hemorrhage, mechanical obstruction or perforation.
